Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer

PURPOSE: Third-generation epidermal growth factor receptor (EGFR) inhibitors like nazartinib are active against EGFR mutation–positive lung cancers with T790M-mediated acquired resistance to initial anti-EGFR treatment, but some patients have mixed responses. METHODS: Multiple serial tumor and liqui...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Precis Oncol
Main Authors: Piotrowska, Zofia, Hazar-Rethinam, Mehlika, Rizzo, Coleen, Nadres, Brandon, Van Seventer, Emily E., Shahzade, Heather A., Lennes, Inga T., Iafrate, Anthony J., Dias-Santagata, Dora, Leshchiner, Ignaty, Jessop, Nicholas A., Hu, Haichuan, Digumarthy, Subba R., Nagy, Rebecca J., Lanman, Richard B., Moody, Susan, Niederst, Matthew J., Engelman, Jeffrey A., Hata, Aaron N., Corcoran, Ryan B., Sequist, Lecia V.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
Original Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6097183/
https://ncbi.nlm.nih.gov/pubmed/30123863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.17.00263
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados